Fundraising FoxBellicum Pharmaceuticals
AcquiredHouston, US · 3 known investors
Find your way into Bellicum Pharmaceuticals
Sign up to see every warm intro you have to Bellicum Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bellicum Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by The University of Texas MD Anderson Cancer Center February 2024 · $8.1M ($8.1 million in cash for substantially all assets) · source ↗
Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
Founders & leadership
DM
David M. SpencerFounder
KM
Ken MoseleyExecutive
TJ
Thomas J. FarrellExecutive
AM
Annemarie MoseleyExecutive
JS
Joseph SenesacExecutive
Board
KM
JF
James F. BrownBoard director
FM
Frank McGuyerBoard director
DK
Dennis K. StoneBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$114.2M disclosed across 2 rounds · 2011–2014
▶$94.4MraisedSep 2014 · 76 investors · PharmaceuticalsRule 506(b)
▶$94.4MraisedSep 2014 · 76 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David M. SpencerExecutive Officer
- Annemarie MoseleyExecutive Officer
- Kevin M. SlawinDirector
- Dennis K. StoneDirector
- James F. BrownDirector
- Frank McGuyerDirector
- Ken MoseleyExecutive Officer
- Thomas J. FarrellExecutive Officer, Director
- Offering amount
- $94.4M
- Amount sold
- $94.4M
- Sales commissions
- $3.1M
- Placement agents
- Jefferies LLC
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.9MraisedMar 2012 · 21 investors · PharmaceuticalsRule 506(b)
▶$19.9MraisedMar 2012 · 21 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ken MoseleyExecutive Officer
- Thomas J. FarrellExecutive Officer, Director
- James F. BrownDirector
- Annemarie MoseleyExecutive Officer
- Joseph SenesacExecutive Officer
- Frank McGuyerDirector
- David M. SpencerExecutive Officer
- Dennis K. StoneDirector
- Kevin M. SlawinExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $19.9M
- Minimum investment
- $1M
- First sale
- Nov 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Bellicum Pharmaceuticals do?
- Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
- Who founded Bellicum Pharmaceuticals?
- Bellicum Pharmaceuticals was founded by David M. Spencer.
- Who are Bellicum Pharmaceuticals's investors?
- Bellicum Pharmaceuticals's investors include Foresite Capital, RA Capital, Rapha Capital Management, LLC.
- How much funding has Bellicum Pharmaceuticals raised?
- Bellicum Pharmaceuticals has disclosed $114.2M raised across 2 rounds.
- Where is Bellicum Pharmaceuticals headquartered?
- Bellicum Pharmaceuticals is headquartered in Houston, US.